Reply to ‘Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favorable prognosis' by Hou, H-A et al.
Letter to the Editor
Reply to ‘Heterogeneity within AML with CEBPA mutations; only
CEBPA double mutations, but not single CEBPA mutations are
associated with favorable prognosis’
H-A Hou
1, L-I Lin
2, C-Y Chen
1 and H-F Tien
1,*
1Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, Taipei, Taiwan;
2Department of Clinical Laboratory
Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan
British Journal of Cancer (2009) 101, 738–740. doi:10.1038/sj.bjc.6605207 www.bjcancer.com
Published online 21 July 2009
& 2009 Cancer Research UK
                  
Sir,
We read with great interest the recent study by Pabst et al
(2009) disclosing that there is relevant prognostic heterogeneity
within AML patients with CEBPA mutations and only CEBPA
double mutations (CEBPA
double-mut), but not single mutations
(CEBPA
single-mut), are associated with favourable prognosis in the
AML patients. However, the reason why CEBPA
single-mut patients
have a poorer outcome than CEBPA
double-mut patients remains
unclear and a comprehensive study to evaluate the biological
difference between these two groups is still lacking.
In this study, we investigated the prevalence and clinical
relevance of CEBPA
double-mut and CEBPA
single-mut and their
association with other genetic changes in a large cohort of
543 consecutive de novo AML patients at the National Taiwan
University Hospital (NTUH). This study was approved by the
Institutional Review Board of NTUH; written informed consents
were obtained from all participants in accordance with the
Declaration of Helsinki. CEBPA mutations were detected by
genomic-DNA PCR and direct sequencing as described earlier
(Lin et al, 2005). Mutational analyses of FLT3/ITD, FLT3/TKD
N-RAS, K-RAS, NPM1, CEBPA, KIT, AML1 and MLL/PTD were
carried out as previously described (Hou et al, 2008).
Among the 543 AML patients recruited, we identified 71 (13.1%)
patients with CEBPA mutations, including 47 CEBPA
double-mut
and 24 CEBPA
single-mut. Compared with patients who have
CEBPA
double-mut, those with CEBPA
single-mut had lower incidences
to express HLA-DR (65 vs 96%, P¼0.0014), CD7 (44 vs 79%,
P¼0.006) and CD15 (35 vs 85%, Po0.0001), but a higher
incidence to express CD56 (35 vs 11%, P¼0.038) on leukemia
cells. Apart from this, there were no differences in other clinical
parameters including age, sex, haemogram, LDH level, FAB
subtype and karyotype between these two groups. No matter
CEBPA
single-mut or CEBPA
double-mut, the mutation disappeared at
complete remission in all patients who had paired bone marrow
samples for analysis and reappeared at relapse.
Patients with CEBPA
single-mut had a higher incidence of NPM1
mutation than those with CEBPA
double-mut (4/24, 16.7 vs 0%,
P¼0.0109). There was also a higher incidence of concurrent
mutation of FLT3/ITD, FLT3/TKD, AML1/RUNX1 or MLL/PTD in
CEBPA
single-mut patients than in CEBPA
double-mut patients (20.8 vs
10.6%, 12.5 vs 4.3%, 8.3 vs 2.1% and 4.2 vs 0%, respectively), but the
difference did not reach statistical significance. However, when
combined together, simultaneous alteration of any one of these four
mutations occurred more frequently in the former group than in the
latter (37.5 vs 14.9%, P¼0.039). More intriguingly, all four
CEBPA
single-mut patients with NPM1 mutation also simultaneously
had FLT3/ITD (2 patients), FLT3/TKD (1 patient), or both (1 patient).
In terms of outcome, CEBPA
double-mut patients had a higher
complete remission rate than CEBPA
single-mut patients (91 vs 56.3%,
P¼0.0051). The patients with CEBPA
double-mut had a significant
longer overall survival (OS) than those with CEBPA
wild or
CEBPA
single-mut (median: not reached vs 29.8 months and 7.5
months; P¼0.013 and P¼0.001, respectively; among 3 groups,
P¼0.007, Figure 1A). The same was also true for disease-free
survival (DFS) (median: 59 months vs 8 months and 4 months;
P¼0.016 and P¼0.027, respectively; among 3 groups, P¼0.037).
Among the subgroup of patients with normal karyotype,
the differences in OS and DFS between CEBPA
double-mut and
CEBPA
single-mut patients were still obvious (P¼0.002 and
P¼0.019, respectively, Figure 1B). The multivariate analysis
clearly identified CEBPA
double-mut, but not CEBPA
single-mut as
an independent prognostic factor for OS and DFS (hazard ratio
0.362, 95% CI 0.182–0.721, P¼0.004 and hazard ratio 0.426, 95%
CI 0.263–0.691, P¼0.001, respectively, Table 1).
From the above findings, we hypothesise that the close
association of CEBPA
single-mut with CD56 expression (Raspadori
et al, 2001) and other poor-risk genetic alterations, such as FLT3/
ITD, FLT3/TKD, MLL/PTD and AML1/RUNX1, (Schnittger et al,
2000; Harada et al, 2004; Whitman et al, 2008) may partially
explain why CEBPA
single-mut predisposes to inferior outcome than
CEBPA
double-mut. We also observed a trend of shorter OS in
CEBPA
single-mut patients who had concurrent FLT3/ITD, FLT3/
TKD,MLL/PTD or AML1/RUNX1 mutation than those who did not
(P¼0.064, Figure 2).
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www.bjcancer.comIn summary, about one-third of patients with CEBPA mutations
had CEBPA
single-mut, which were closely associated with CD56
expression but inversely correlated with HLA-DR, CD7 and CD15
expression. Compared with patients who have CEBPA
double-mut,
those with CEBPA
single-mut had a higher incidence of concurrent
FLT3/ITD, FLT3/TKD, MLL/PTD or AML1/RUNX1 mutation and
had a poorer prognosis. This study provides evidences indepen-
dently from previous ones, stressing the differences in biological
characteristics between CEBPA
single-mut and CEBPA
double-mut
AML and their possible prognostic implication. Further studies
are necessary to clarify whether the close association of
CEBPA
single-mut with CD56 expression and other poor-risk gene
alterations contributes to the poorer outcome of this group of
patients.
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Figure 1 Kaplan–Meier survival curves of overall survival (OS) stratified
by different status of CEBPA mutation at diagnosis among total patients
(A) and in the subgroup of patients with normal karyotype (B). Only
patients receiving standard chemotherapy were enrolled into survival
analysis. Among total patients, P-value for OS of CEBPA
double-mut vs
CEBPA
wild patients was 0.013, for CEBPA
double-mut vs CEBPA
single-mut
patients, 0.001, and among three groups, 0.007 (A). In the subgroup of
patients with normal karyotype, P-value for OS of CEBPA
double-mut vs
CEBPA
wild patients was 0.01, for CEBPA
double-mut vs CEBPA
single-mut patients
was 0.002 and among three groups it was 0.005 (B).
Table 1 Multivariate analysis for overall and disease-free survival
a
Overall survival Disease-free survival
Variables HR (95% CI) P value HR (95% CI) P value
CEBPA
single-mut 1.614 (0.743–3.508) 0.227 1.164 (0.630–2.149) 0.629
CEBPA
double-mut 0.362 (0.182–0.721) 0.004 0.426 (0.263–0.691) 0.001
Karyotype 2.388 (1.774–3.215) o0.001 2.387 (1.899–3.002) o0.001
Age
b 2.741 (1.959–3.836) o0.001 1.488 (1.137–1.948) 0.004
Sex
c 0.937 (0.670–1.311) 0.704 1.107 (0.848–1.445) 0.456
WBC
d 1.524 (1.051–2,209) 0.026 1.396 (1.031–1.890) 0.031
FLT3/ITD 1.798 (1.232–2.624) 0.002 1.843 (1.350–2.515) o0.001
AML1/RUNX1 1.755 (1.036–2.972) 0.036 1.410 (0.909–2.187) 0.125
NPM1 0.500 (0.317–0.789) 0.003 0.482 (0.332–0.699) o0.001
Abbreviations: CI¼confidence interval; HR¼hazard ratio.
aIncluding 397 patients
who received standard chemotherapy. Those patients who did not receive
chemotherapy or only low dose chemotherapy were excluded.
bAge greater than
50-years old vs less than 50-years old.
cMale vs female.
dWBC greater than 50 10
9/l
vs less than 50 10
9/l.
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Figure 2 Kaplan–Meier survival curves of overall survival (OS) in the
CEBPA
single mut patients with and without concurrent FLT3/ITD, FLT3/TKD,
MLL/PTD or AML1/RUNX1 mutation.
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